Joining forces: a call for greater collaboration to study new medicines in children and adolescents with type 2 diabetes
Diabetes Care
.
2014 Oct;37(10):2665-7.
doi: 10.2337/dc14-0494.
Authors
Janina Karres
1
,
Valerie Pratt
2
,
Jean-Marc Guettier
2
,
Jean Temeck
3
,
William V Tamborlane
4
,
David Dunger
5
,
Cristina Bejnariu
6
,
Carine De Beaufort
7
,
Paolo Tomasi
6
Affiliations
1
Paediatric Medicines, European Medicines Agency, London, U.K. janina.karres@ema.europa.eu.
2
Division of Metabolism and Endocrinology Products, U.S. Food and Drug Administration, Silver Spring, MD.
3
Office of Pediatric Therapeutics, U.S. Food and Drug Administration, Silver Spring, MD.
4
Center for Clinical Investigation, Yale School of Medicine, New Haven, CT.
5
Department of Paediatrics, University of Cambridge, Cambridge, U.K.
6
Paediatric Medicines, European Medicines Agency, London, U.K.
7
Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
PMID:
25249667
DOI:
10.2337/dc14-0494
No abstract available
Publication types
Editorial
MeSH terms
Adolescent
Child
Cooperative Behavior*
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / epidemiology
Drug Discovery / trends*
Drug Industry / trends*
Europe
Humans
Prevalence
United States
Grants and funding
G0800661/MRC_/Medical Research Council/United Kingdom